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Prognostic significance of telomerase activity in neuroblastoma like tumours
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Magdalena Reich4, Alicja Chybicka2
I n t r o d u c t i o n.  Telomerase is an enzyme responsible for maintaining the length of telomeres – end structures of
chromosomes indispensable for the proper functioning and stabilization of genetic material of eucaryotic cells. The presence
of activated telomerase in neoplastic cells prevents telomere shortening and is responsible for cell immortality.
T h e  a i m  o f  t h e  s t u d y  was to evaluate telomerase activity in neuroblastoma-like tumours and to estimate the influence
of telomerase activity on patient outcome. Correlations between telomerase activity and other prognostic factors were also
investigated.
Pa t i e n t s.  33 tissue samples obtained from 30 patients aged between 1 and 75 months (19 boys and 11 girls) were analysed.
Neuroblastoma was diagnosed in 24 patients (80%), ganglioneuroblastoma in 4 (13.3%) and ganglioneuroma in 2 (6.7%)
patients.
M e t h o d s.  Tissue samples were frozen immediately after biopsy and stored in -80°C until the analysis. All samples were
checked with alkaline phosphatase reaction in order to exclude false negative results. For telomerase activity evaluation two
independent methods were used: TRAP method (Telomerase Repeat Amplification Protocol; TRAP®eze Telomerase Detection
Kit, Intergen Company, S7700) and ELISA method (TeloTAGGG Telomerase PCR ELISA, Roche Diagnostics, 2013789).
Re s u l t s.  Telomerase activity was stated in 9 tissue samples of primary tumours, and in a regional lymph node infiltrated by
neoplasm cells and in a metastatic relapse in the mediastinum. Neuroblastoma with telomerase activity presented as a more
advanced malignancy (larger tumours with infiltration of regional lymph nodes or disseminated disease) and more common
with prognostically unfavourable MYCN amplification. Patients with telomerase activity had significantly poorer outcome, as
compared to patients without telomerase activity (5-year EFS 0.61 and 0.15, respectively; p=0.01).
C o n c l u s i o n.  The assessment of telomerase activity before the onset of oncological treatment may aid patient stratification
and the choice of optimal therapy. The influence of telomerase on clinical outcome supports the theory of its pathogenetic role
in neuroblastoma, so the enzyme could be a possible target for new antitumour inhibiting drugs.
Rokownicze znaczenie aktywnoÊci telomerazy w guzach typu neuroblastoma
W s t ´ p.  Telomeraza jest enzymem odpowiedzialnym za utrzymanie sta∏ej d∏ugoÊci telomerów, koƒcowych struktur chromo-
somalnych, niezb´dnych do prawid∏owej funkcji i stabilnoÊci materia∏u genetycznego komórek eukariotycznych. ObecnoÊç zak-
tywowanej telomerazy w komórkach nowotworowych zapobiega skracaniu telomerów, a tym samym powoduje, ˝e komórki te
stajà si´ nieÊmiertelne.
C e l e m  p r a c y  by∏o zbadanie aktywnoÊci telomerazy w guzach typu neuroblastoma i próba oceny wp∏ywu tego parametru
na rokowanie w grupie chorych z tym nowotworem. Porównano ponadto zale˝noÊç wyst´powania aktywnej telomerazy z in-
nymi czynnikami prognostycznymi.
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Study background
Neuroblastoma-type tumours are one of the most
common malignancies in children. Their common feature
is their origin – from ganglion neurons of the sympathetic
system. Most common neuroblastoma localizations
include the suprarenal glands and the paravertebral
ganglia. Neuroblastoma-type tumours may be divided
into a number of subtypes, which differ as to histology,
biology and clinical features. One of these subtypes covers
highly malignant, undifferentiated neuroblastomas; the
ganglioneuroblastomas show some degree of maturity,
while ganglioneuromas are highly differentiated, mainly
benign tumours [1, 2].
In this particular group of tumours one may observe
relatively common spontaneous tumour regression –
especially in children below 1 year of age – and, also,
idiopathic tumour maturation towards high differentation.
Such varied tumour biology makes patient stratification
and choice of treatment difficult. On the one hand the
possibility of spontaneous regression or maturation offers
a chance of successful treatment even with less intensive
therapy; on the other hand inadequate oncological
treatment may lead to disease progression and death.
Recently a wide number of studies have been conducted,
aimed at analyzing the biological features of this
malignancy and at preparing a system of stratification,
which would be based on prognostic factors, thus allowing
to decide upon the best choice of treatment. In the course
of these studies a number of biological prognostic factors
have been identified (e.g. the number of copies of the
MYCN oncogene, the presence of chromosome 1 short
arm deletion, DNA ploidy, the presence of the tyrosine
kinase receptor – TRK-A – for the neural growth factor)
[3]. All these have become useful in standard diagnostics.
However, we are still searching for new data which would
allow for more precise prognosis. The activity of
telomerase, the enzyme responsible for unlimited
multiplication of malignant tumours, is one of these
promising factors [4-7].
Telomerase is a ribonucleoprotein enzyme which is
responsible for maintaining the length of telomeres
unchanged. Telomers are highly specific chromosomal
end structures which consist of short DNA repetitions
(TTAGGG) and proteins. They are necessary to maintain
the correct functioning and stability of the genetic
material of eucaryotic cells [8] as they prevent chromo-
some adhesion, incorrect recombination and degradation.
They also facilitate complete replication, thus preventing
the loss of genes necessary for cell survival in the course
of cellular DNA replication. DNA polimerase, which is
responsible for replication, is incapable of complete
copying of the ends of linear DNA. In healthy cells every
division of the genetic material causes unavoidable
shortening of chromosomes and loss of a DNA fragment.
The presence of telomeres prevents the loss of important
genes, however each course of replication causes the loss
of repeated telomere sequences. This limits the number of
divisions achieved by a single cell. They may only continue
until the moment when telomeres reach critical length
(approx. 3 kbp) [9, 10]. A number of cells derived from
structures where regeneration is a necessity (sex cells,
embryonal cells, stem cells, intestinal crypt cells, cells of
the sheath of the hair, hepatocytes) are capable of unli-
mited division due to the presence of active telomerase,
the enzyme capable of rebuilding lost telomere fragments.
The activation of telomerase is one of the most
characteristic features of neoplastic transformation. Due
to this phenomenon neoplastic cells achieve the ability
of constant division, and thus become immortal. It has
been observed that in some types of malignancy the
identification of active telomerase is associated with
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Pa c j e n c i.  Materia∏ badawczy stanowi∏y 33 wycinki tkanki nowotworowej, pobrane od 30 pacjentów w wieku od 1 do 75 mie-
si´cy (19 ch∏opców i 11 dziewczynek). U 24 chorych (80%) rozpoznano neuroblastoma, u 4 (13,3%) ganglioneurobla-
stoma, u pozosta∏ych 2 (6,7%) ganglioneuroma.
M e t o d a.  BezpoÊrednio po pobraniu materia∏ tkankowy zamra˝ano w ciek∏ym azocie i przechowano w stanie zamro˝enia do
czasu podj´cia analizy. W celu wykluczenia wyników fa∏szywie ujemnych, we wszystkich próbkach metodà dot blot oznaczo-
no aktywnoÊç fosfatazy alkalicznej. Do oznaczenia aktywnoÊci telomerazy pos∏u˝ono si´ dwoma niezale˝nymi metodami: pro-
cedurà TRAP (Telomerase Repeat Amplification Protocol; TRAP®eze Telomerase Detection Kit, Intergen Company, S7700)
oraz metodà ELISA (TeloTAGGG Telomerase PCR ELISA, Roche Diagnostics, 2013789).
W y n i k i.  AktywnoÊç telomerazy stwierdzono w materiale pochodzàcym z guza pierwotnego u 9 pacjentów, a tak˝e w nacie-
czonym nowotworowo w´êle ch∏onnym oraz we wznowie przerzutowej choroby w Êródpiersiu. W przypadku guzów z dodatnià
aktywnoÊcià telomerazy proces chorobowy by∏ bardziej zaawansowany (guzy du˝ych rozmiarów, cz´stsze zaj´cie w´z∏ów
ch∏onnych, cz´Êciej stadium IV), a tak˝e cz´Êciej obserwowano obecnoÊç niekorzystnej prognostycznie amplifikacji onkoge-
nu MYCN. Pacjenci z dodatnià aktywnoÊcià telomerazy cechowali si´ tak˝e znamiennie gorszym rokowaniem, w porównaniu
do pacjentów telomerazonegatywnych (5-letnie EFS odpowiednio 0,61 i 0,15; p=0,01).
W n i o s k i.  Oznaczenie aktywnoÊci telomerazy przed rozpocz´ciem leczenia przeciwnowotworowego mo˝e pomóc w stratyfi-
kacji prognostycznej chorych i wyborze najlepszej metody terapeutycznej. Wp∏yw telomerazy na rokowanie Êwiadczy o udzia-
le tego enzymu w patogenezie neuroblastoma i dlatego sugeruje si´ poszukiwanie nowych leków przeciwnowotworowych, ha-
mujàcych aktywnoÊç tego enzymu.
Key words: telomerase, neuroblastoma, children’s neoplasms
S∏owa kluczowe: telomeraza, neuroblastoma, nowotwory dzieci´ce
poorer prognosis [9-12]. Studies of telomerase activity in
neuroblastomas suggested, that the enzyme plays an
important part in the pathogenesis and clinical course of
these tumours [4-7]. The aim of the present study was to
investigate the influence of telomerase activity on the
prognosis of patients with embryonal neuroblastoma. We
also analysed the relations between telomerase activity
and a number of clinical parameters and evaluated the
possibility of applying this feature as an element of
routine diagnostics.
Material
Telomerase activity was investigated in 33 tissue samples
obtained in the course of diagnostic biopsy or tumour resection
from 30 patients (19 boys, 11 girls) aged from 1 to 75 months
(median age: 15.5 months) with neuroblastoma-like tumour. In
all cases the tissue samples underwent histological verification by
another pathologist in order to confirm the initial diagnosis and
to decide, whether the obtained tissue sample is representative
for the tumour and may be used for further analysis. In the case
of 19 patients the material was obtained before the onset of
treatment (63.3%) and in the remaining 11 patients (36.7%)
the samples were obtained during chemotherapy. In the case
of one child we also obtained an infiltrated lymph node, in
another – a malignant lesion present in the neighbouring
suprarenal gland and in yet another – telomerase activity was
analysed in a tissue sample obtained from the metastatic relapse
found in mediastinum.
In 24 patients (80%) neuroblastoma, in 4 (13.3%) –
ganglioneuroblastoma and in the remaining 2 (6.7%) –
ganglioneuroma were diagnosed. In 26 patients (86.7%) the
primary tumour was located in the suprarenal gland, in 3 (10%)
in the mediastinum and in 1 child (3.3%) within the structures of
the neck. Regional lymph node involvement was observed in 14
patients (46.7%). At the time of diagnosis distant metastases
were present in 17 patients (56.7%) – usually to the liver (6 pts.),
bone marrow (5 pts.) and bones (4 pts.). Median follow-up time
for the entire group was 26.5 months, median follow-up time
for patients surviving till this day was 29 months.
Methods
S p e c i m e n s
The tissue samples were preserved in liquid nitrogen (-170°
Centigrade) directly after obtaining. Samples from 27 patients
were kept at –80° Centigrade, from the remaining 3 patients at
–20° Centigrade until analysis. Before defrosting the samples
were placed into teflon jars with carbide-volframe beads (B.
Braun Biotech International; Melsungen) and homogenized in
a microdismembrator (2000 r.p.m. over 30 seconds). In order to
avoid telomerase inactivation all further processing took place
“on ice” in 0° Centigrade. The homogenized samples were
dissolved in the CHAPS buffer (supplied with the TRAPeze
kit®) at a ratio of 25 µl per 20-50 µg of tissue adding an RNA-ase
inhibitor (Gibco Brl. 40 U/µl) at a ratio of 5 µl per 1 ml of
CHAPS buffer. After 30 min. incubation “on ice” the samples
were centrifuged (12000 r.p.m. at 4° for 20 minutes). 25 µg of the
supernatant were taken for analysis of protein content, the
remaining part was frozen in liquid nitrogen and kept at -80°
Centigrade until further analysis.
A l c a l i n e  p h o s p h a t a s e  a c t i v i t y
In order to avoid false negative results alcalic phosphatase
activity was determined in all samples by the dot-blot method.
1µl of the analysed tissue sample (CHAPS buffer lysate) was
placed on a nylon membrane (Nylon Membrane, Roche) and
blocked with a 1% solution of powdered milk dissolved in
maleinian acid buffer (pH 7.5; 30 min), rinsed twice on a shaker
in maleinian acid buffer (pH 7.5) with an addition of 0.1%
Tween solution (10 min. each time). Then the membrane was
balanced in a solution containing 100 mM TRIS base and 50
mM MgCl2 for every 500 ml of buffer. Next we added 500 µl of
CSPD “ready to use” (Roche, 1755633) and incubated in the
dark for 5 min. Thus prepared membrane was incubated for 20
min. in 37° Centigrade in a radiographic cassette. In order to
obtain the results we exposed the chemiluminescence film
(Hyperfilm™ ECL™ igh Performance Chemiluminescence Film,
Amersham Pharmacia Biotech) for 2-5 minutes, and then
exposed it.
E v a l u a t i o n  o f  p r o t e i n  c o n t e n t
We estimated the standard curve using the standard BSA
solution (bovine serum albumin – 1 mg/ml supplied with the
kit). In order to estimate the standard curve we used the follo-
wing standard solutions: 50 µl BSA, 40 µl BSA + 10 µl H2O,
30 µl BSA + 20 µl H2O, 20 µl BSA + 30 µl H2O, 10 µl BSA +
40 µl H2O and 50 µl H2O. The analysed samples were prepared
in two concentrations – 1:5 and 1:10. We added 1 ml of
a solution obtained by adding 20 µl of 4% CuSO4 (Sigma,
C2284) per 1 ml of BCA (Bicinchoninic Acid Solution; Sigma,
B9643) and incubated in a water bath in 37° Centigrade for
30 min. Using the standard solutions we prepared the standard
curve. Next the absorbancy of the analysed samples at wave
length λ=562 nm was measured and protein content was
calculated.
E v a l u a t i o n  o f  t e l o m e r a s e  a c t i v i t y
In order to obtain reliable results we estimated telomerase
activity in each sample using two different methods – TRAP
(Telomerase Repeat Amplification Protocol) with the TRAPeze®
Telomerase Detection Kit (Intergen Company, S7700) and the
ELISA method with the TeloTAGGG Telomerase PCR ELISA
PLUS (Roche, 2013789).
T h e  T RA P  m e t h o d
2 µl of previously prepared samples containing 0.25 µg/µl and
0.025 µg/µl protein dissolved in the CHAPS buffer were put
into free RNA-ase vials. Simultaneously we prepared positive
(1 µl TSR8 supplied with the kit + 1 µl dH2O) and negative
(2 µl CHAPS buffer) controls. Then we added 48 µl of the
“Master Mix” solution to each vial (“Master Mix” solution was
prepared with the following substances supplied with the kit:
10xTRAP Reaction Buffer – 5.0 µl, TS Primer – 1.0 µl, 50x
dNTP Mix – 1.0 µl, TRAP Primer Mix – 1.0 µl, Taq-Polymerase
– 0.4 µl (2U), dH2O – 39.6 µl). We performed the PCR
(Polymerase Chain Reaction) using 33 and 35 amplification
cycles. The PCR was performed according to the following
scheme: incubation in 30° Centigrade for 30 min; next incubation
in 90° Centigrade for 2 mins, next – 33 or 35 cycles, each
including 30 s. 57° Centigrade + 30 s. 94° Centigrade. When
the PCR was complete we added dye to each sample (0.25%
Bromophenol Blue/0.25% Xylene cyanol in 50% glycerol/50mM
EDTA) and placed it on non-denaturating gel (6% Long Rager
Gel). The results were obtained with the aid of a sequencer –
DNA Sequencer Model 4000 (MWG-Biotech, Ebersberg) –
read-out conditions: 35 mA, 31W, approx. 1000V, 50° Centigrade;
read-out time: approx. 40 min. Samples were considered positive
if at least three strias were discerned, beginning with the stria for
50 bp DNA and, additionally, a 36 bp stria which providing the
internal control of PCR correctness. Samples were considered
negative if only the 36 bp stria was present. If the 36 bp stria was
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absent the sample was considered as non-interpratable and the
analysis was repeated until a conclusive result was obtained.
T h e  E L I S A  m e t h o d
In this method we used the TeloTAGGG Telomerase PCR
ELISA PLUS kit. 2 µl of each sample were added to 30 µl of the
reagent, which consisted of: biotynylated telomerase substrate
P1-TS, the P2 binding primer, nucleotides, DNA Taq-polymerase
and 5 µl 0.001 amol/µl standard DNA 216 bp of length (sub-
strates supplies with the kit). Each analysis contained a positive
control, obtained aforehand by adding 1 µl 0.001 amol/µl DNA
the sequence of which was identical with the telomerase product
which consisted of 8 repetitions of telomere sequences (TS8)
and with a negative control obtained by adding 1 µl of the
CHAPS buffer to the reagent. Apart from this a separate
negative control was prepared for each sample by heating the
sample to 94° Centigrade for 20 min. Nuclease-free water was
added to all samples up to 50 µl and the samples were incubated
for 30 min. at 37° Centigrade and then inactivated by heating to
94° Centigrade over 5 min. Then 31 cycles of the PCR were
performed (one cycle consisted of 94° Centigrade for 30 seconds,
50° Centigrade for 30 seconds and 72° Centigrade for 90
seconds). The last stage of the PCR was incubation in 72°
Centigrade for 10 minutes. Then 2.5 µl of the PCR products
were added to 10 µl of the denaturating reagent and incubated at
room temperature for 10 minutes. After incubation we added
100 µl of hybrydising buffer to each sample and incubated it
for 2 hours in 37° Centigrade. After this time all the samples
were placed on a streptavidine-coated MTP (microtiter plate),
covered with self-adhesive film and incubated at the same
temperature for one more hour. Afer incubation the solution
was decanted and each fossa was carefully rinsed with the rinsing
solution. Next 100 µl of policlonal sheep antibody conjugated
with horseradish peroxidase (Anti-DIG-HRP) was added to
each fossa, covered with self-adhesive film and incubated for
another 30 min. at room temperature on a shaker (300/min).
Then the solution was decanted and each fossa was carefully
rinsed with the rinsing solution. In the next stage 100 µl of the
TMB reagent (supplied with the kit) was added to each fossa and
incubated on the shaker (200/min) for 20 minutes. As the last
step 100 µl of the reaction-inhibiting reagent (supplied with the
kit) was added and absorbance (A) was read for each sample at
a wave length of 450 nm, with the use of a reference wave length
of 590 nm using the ELISA 340 ATTC reader (SLT Labinstru-
ments, Crailsheim). The negative control was considered valid, if
the difference in absorbance (A450nm – A590nm) was less than
0.1. The sample was considered telomerase-positive if the
difference in absorbance (sample absorbance minus absorbance
of the thermically inactivated sample) was twice as high as
background absorbance. The results of the ELISA test are
presented in Table I.
Te l o m e r a s e  a c t i v i t y
All the patients were divided into three groups depending upon
the telomerase activity determined in the tissue samples obtained
from the tumour. The groups covered patients with high
telomerase activity, low telomerase activity and no telomerase
activity. The group with high telomerase activity consisted of
patients in whom this phenomenon was observed both in the
0.25 µg/µl and 0.025 µg/µl. The group with low telomerase
activity consisted of patients in whom this phenomenon was
observed only in the 0.25 µg/µl sample. The group with no
telomerase activity consisted of patients in whom no such activity
was observed in any of the samples.
S t a t i s t i c a l  a n a l y s i s
Statistical analysis was performed using the Statistica® 97Pl for
Windows® software. The differences in the frequency of
parameter appearance between the analysed groups were
evaluated with the Fisher’s exact test. The event-free survival
(EFS) curve was estimated according to the Kaplan-Meier
method [14] beginning with the day of therapy onset to the day
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Table I. ELISA test results – values of absorbance measured at wave length of 450 nm 
reduced by the value of background absorbance measured at wave length of 590 nm
Patient Protein concentration 0.25 µg/µl Protein concentration 0.025 µg/µl
Negative control Analyzed sample Telomerase activity Negative control Analyzed sample Telomerase activity
1 0.035 0.030 none 0.040 0.023 none
2 0.067 0.062 none 0.056 0.055 none
3 0.078 0.061 none 0.062 0.058 none
4 0.059 0.055 none 0.078 0.060 none
5 0.027 0.047 none 0.024 0.035 none
6 0.085 1.787 present 0.081 1.690 present
7 0.055 1.352 present 0.021 1.282 present
8 0.065 0.154 present 0.061 0.073 none
9 0.078 0.062 none 0.059 0.057 none
10 0.047 0.041 none 0.044 0.043 none
11 0.034 0.062 none 0.028 0.030 none
12 0.058 0.037 none 0.025 0.032 none
13 0.057 0.370 present 0.610 0.136 present
14 0.043 0.441 present 0.052 1.560 present
15 0.028 0.709 present 0.031 0.404 present
16 0.037 0.030 none 0.046 0.026 none
17 0.069 0.077 none 0.055 0.056 none
18 0.098 1.424 present 0.058 0.490 present
19 0.049 0.462 present 0.079 1.090 present
20 0.102 0.085 none 0.062 0.068 none
21 0.069 0.058 none 0.053 0.053 none
22 0.048 0.336 present 0.031 0.188 present
23 0.078 0.069 none 0.054 0.058 none
24 0.027 0.037 none 0.033 0.035 none
25 0.057 0.062 none 0.063 0.065 none
26 0.050 0.148 present 0.046 0.066 none
27 0.026 0.836 present 0.031 0.561 present
of failure or to the day of the most recent follow-up. Failure
was defined as disease progression, recurrence or patient death
(regardless of the cause). Differences between survival curves
were verified with the log-rank test [15]. Statistical analysis was
performed at the confidence level of α=0.05. The significance
level was assumed to be p<0.05.
Results
The two methods applied for the evaluation of telomerase
activity showed a highly significant, positive correlation of
the results (R=0.8; p<0.0001). All the analysed tissue
samples presented positive reactions for alkaline
phosphatase activity (data not shown), however in the
case of 3 samples stored at -20° Centigrade additional
RNA isolation and division revealed significant RNA
degradation (data not shown). These samples did not
reveal telomerase activation, however, due to the RNA
degradation they were excluded from further analysis as
doubtful.
Results obtained from the remaining 27 patients (27
samples obtained from the primary tumours and those
additionally obtained from 3 patients from this group,
i.e. one metastatic lymph node, one sample obtained from
a tumour found in the neighbouring suprarenal gland
and one sample obtained from a metastatic lesion in the
mediastinum) are presented in Table II (including detai-
led clinical data). Altogether, telomerase activity was
observed in the material obtained from the primary
tumour of 11 patients (high in 9 patients and low in 2
patients). Positive telomerase activity were also found in
the sample from the metastatic lymph node and in the
material obtained from recurred case. Tumours with high
telomerase activity were, in general, larger, i.e. over 10 cm
in diameter (p=0.03). Here it is necessary to add that in
all stage IVs cases the primary tumours were less than
10 cm in diameter. Moreover, MYCN oncogene ampli-
fication was more common in the case of tumours with
high telomerase activity, as well as were regional lymph
node involvement and stage IV (the differences were on
the verge of significance: 0.1 > p > 0.05; see Table III).
Also, in this group of patients, treatment failure was more
often noticed (p=0.03).
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Table II. Patient characteristics
Patient Age Stagea) Histologyb) Therapy N Tumour size Amp Telomerase Patient state
(gender) prior to biopsy Status (cm) MYCN activity
1 58 (m) 1 GN mature none N0 2.5x2x1.5 - none CR
2 41 (f) 2 GNB none N0 4x4x4 - none CR
3 10 (m) 2 NBL d none N0 6x5.5x3 - none CR
4 2 (f) 2 NBL d none N0 5x4.5x3 n.d. none CR
5 13 (f) 2 NBL d none N0 5.5x4.5x4 - none CR
6 9 (f) 2 NBL ud none N+ 5x4x4 - high LR, 2. CR
6* 9 (f) 2 NBL ud none N+ - - high LR, 2. CR
7 71 (f) 3 GNB none N+ 19x14x6.5 - high CR
8 72 (m) 3 GNB yes N+ 5x4x4 n.d. low CR
9 49 (m) 3 NBL d yes N+ huge - none MR, RC
(>10 cm)
9** 49 (m) - NBL d yes N+ - n.d. high MR, RC
10 7 (m) 3 NBL ud yes N+ huge - none LR, 2. CR
(>10 cm)
11 12 (m) 3 NBL pd yes N0 6.2x3.7x3 - none SM, death
12 12 (m) 3 NBL ud none N0 n.d. - none CR
13 44 (m) 4 GN maturing yes N+ 7x7x6 - high CR
14 11 (m) 4 GNB yes N+ 6.1x4.8x4 + high LR, death
15 75 (m) 4 NBL d yes N0 10x7x5 - high LR, death
16 3 (f) 4 NBL ud none N+ 6x5x5 - none CR
17 28 (f) 4 NBL ud yes N+ 9x7.5x5.5 + none MR, death
18 21 (f) 4 NBL d none N+ 10x8.5x8 + high MxR, death
19 51 (m) 4 NBL ud yes N+ 11x8x6 n.d. high MR, death
20 48 (m) 4 NBL d yes N+ 3x3x2 n.d. none MR, death
21 54 (m) 4 NBL d yes N+ 9.2x8.4x5 n.d. none PR, death
22 18 (m) 4 NBL pd none N+ huge - high LR, death
(>10 cm)
23 1 (m) 4 NBL ud none N0 7x6x3 - none PR
23*** 1 (m) 4 NBL ud none N0 1x1x1 - none PR
24 4 (m) 4s NBL d none N0 7x7x6 - none CR
25 1 (m) 4s NBL d yes N0 6.1x5.5x5 - none CR
26 6 (m) 4s NBL ud yes N0 5x4x3.5 n.d. low CR
27 7 (f) 4s NBL ud none N0 6.5x4.5x4 + high MR, death
* – lymph node specimen, ** – relapse specimen, *** – specimen from tumour in neighbouring suprarenal gland, age – given in months, 
m – male gender, f – female gender, a) – classification acc. to Evans et al. [13], b) – classification acc. to Shimada et al. [1], GN – ganglioneuroma,
GNB – ganglioneuroblastoma, NBL – neuroblastoma: ud – undifferentiated, pd – poorly differentiated, d – differentiating, Status N – regional
nodal status, N0 – regional lymph nodes negative, N+ – regional lymph nodes involved, Amp MYCN – amplification of MYCN oncogen, 
CR – complete remission, 2. CR – secondary complete remission, PR – partial remission, LR – Local relapse, MR – metastatic relapse, 
MxR – mixed relapse, PR – progression, SM – secondary malignancy (acute lymphoblastic leukaemia), n.d. – no data
An analysis of the estimated event-free survival
(EFS) in the analysed group of children with neuro-
blastoma has shown that patients with none or low
telomerase activity of the tumours presented with
a significantly better prognosis as compared to patients
with high telomerase activity. 5-year EFS was 0.61 and
0.15, respectively; p=0.01 (Figure 1). The other significant
prognostic factors in the included individuals were as
follows: the size of the primary tumour (<10 cm vs. >10
cm: 5-year EFS 0.62 vs. 0.14, respectively; p<0.05),
regional lymph node involvement (N0 vs. N+: 5-year
EFS 0.77 vs. 0.22, respectively; p=0.02), clinical stage (I,
II, III and IVs vs. IV: 5-year EFS 0.65 vs. 0.15,
respectively; p<0.05) and MYCN oncogene amplification
(amp MYCN- vs. amp MYCN +; 5-year EFS 0.57 vs. 0,
respectively; p=0.03).
Discussion
The telomere-telomerase conception has enhanced our
understanding of carcinogenesis. Activated telomerase
allows to rebuild telomeres (which ordinarily shorten in
the course of DNA replication), thus allowing the cells to
undergo unlimited division [8]. In many patients with
neuroblastoma both a decrease in the average telomerase
length and the presence of activated telomerase were
observed [4-7, 16, 17]. Hiyama et al. have presented
a hypothesis which explains the role of telomerase in
neuroblastomas [18]. According to their conception
originally the malignant cells do not contain active
telomerase and in the course of their multiplication the
telomeres become significantly shorter. Those tumours
in which telomerase is not activated are in fact those, in
the case of which we observe regression – probably arising
from apoptosis which is activated when the telomeres are
significantly shortened. However, if any of the malignant
cells during this critical period of time undergo
telomerase reactivation, the active enzyme stabilizes the
telomeres and thus the multiplying cells become
immortal. The cellular clone equipped with activated
telomerase begins to dominate, and the disease takes on
an aggressive course. There are also some interesting
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Table III. Telomerase activity according to the analyzed clinical, histological and genetic prognostic parameters
Parameter Telomerase activity p
Negative Positive value1
Patient age: Mean: 26.9 months
Median: 15.5 months
- < 1 year 8 (44.4%) 3 (33.3%) NS
- ≥ 1 year 10 (55.6%) 6 (66.7%)
Tumour size*:
- < 10 cm 15 (88.2%) 4 (44.4%) 0.03
- ≥ 10 cm 2 (11.8%) 5 (55.6%)
Regional lymph node involvement:
- yes 7 (38.9%) 7 (77.8%) 0.07
- no 11 (61.1%) 2 (22.2%)
Stage:
- Stage I, II, III, IVs 13 (72.2%) 3 (33.3%) 0.06
- Stage IV 5 (27.8%) 6 (66.7%)
MYCN** oncogene amplification:
- yes 1 (7.7%) 4 (57.1%) 0.1
- no 12 (92.3%) 3 (42.9%)
Histology a):
- favourable 12 (66.7%) 6 (66.7%) NS
- unfavourable 6 (33.3%) 3 (33.3%)
Death:
- yes 4 (22.2%) 7 (77.8%) 0.03
- no 14 (77.8%) 2 (22.2%)
* – no data regarding tumour size in one patient, ** – basing on accessible data, a) – classification acc. to Shimada et al. [1], 
1– based on Fisher’s exact test, NS – statistically non-significant
Figure 1. Event-free survival in relation to the level of telomerase
activity within the tumour cells
speculations regarding tumours, in which long telomeres
are observed and in which telomerase activity is present,
but is relatively low [5, 18]. In these patients good
treatment results are quite common. These tumours most
likely originate from poorly differentiated embryonal
cells, in which active telomerase is present from the very
beginning, as a residue of the fetal period. It is, therefore,
assumed that in these tumours better prognosis is
associated with a higher sensitivity to signals stimulating
the maturation of neurons [18].
Our studies have confirmed the significant influence
of telomerase activity on the disease course of neuro-
blastomas. In patients in whom we observed high
telomerase activity within malignant cells the disease was
more advanced (larger primary tumours, stage IV more
common, nodal infiltration) and the patients had poorer
prognosis. It would, therefore, be most advisable to
include this parameter into the standard diagnostics of
children with neuroblastoma – especially because the
prognostic factors analyzed at the moment fail to diffe-
rentiate patients according to prognosis. Further studies
should be performed on a larger group of neuroblastoma
patients, especially in stage IVs (children < 1 year of age
with the presence of liver, bone marrow or skin meta-
stases). Although in a majority of these children we
observe idiopathic tumour regression, yet in some patients
the disease takes on a very aggressive course and leads to
treatment failure [19]. It has been reported, that in this
group of patients the evaluation of telomerase activity
allows to differentiate children in whom one may expect
idiopathic tumour regression, from children in whom the
disease will be aggressive and who, therefore, need
intensive treatment [20]. Evaluation of telomerase activity
may also be very useful for the identification of micro-
metastases and residual disease [21]. On the other hand,
intensive research on substances which may block
telomerase will certainly help to develop new, effective
antitumours drugs, which probable would be charac-
terized by relatively milder side-effects. The results of
such studies appear to be highly promising [22].
It is necessary to remember, that the prognostic
value of telomerase activity depends on the precision of
the analysis. The laboratory conditions must be very stable
in order to consider the results reliable. Because of its
RNA component, which is necessary for the correct
functioning of the enzyme, telomerase is very sensitive
to RNA-ases and undergoes fast inactivation at room
temperature. Therefore, the tissue sample must be placed
in liquid nitrogen directly after sampling and stored at
-80° Centigrade. It appears that the temperature of
ordinary freezers (-20° Centigrade) is too high, and results
obtained after storage in such conditions must be
considered doubtful. Cytostatics, which cause tumour
necrosis, and therefore reduce the number of cells in
which telomerase remains active, also could affect the
results of analysis. In addition some cytostatics specifically
block telomerase (e.g. platin derivatives) [23]. Therefore
chemotherapy applied before obtaining tumour samples
for analysis may also render the interpretation of the
results difficult. In order to unify the results it is necessary
to evaluate telomerase activity in tissue samples obtained
before the onset of therapy. If telomerase activity is
present in tissue samples obtained after the onset of
cytostatic treatment the result must be considered as
a very grave prognostic factor. It is proof of extremely
high proliferative ability, and thus of high aggressiveness
of the tumour. If, however, tissue samples obtained after
the administration of cytostatics appear to possess no
telomerase activity it cannot be considered as proof that
the tumour was, originally, lacking in active telomerase.
The negative result may have been brought on by the
treatment itself and could be not a biological feature of
the tumour [7].
To summarise, we may state that the analysis of
telomerase activity is a valuable method for the
stratification of patients with neuroblastoma. Its
introduction into the routine diagnostics undertaken in
these malignancies will certainly allow to pronounce the
risk for each patient and thus allow to choose the optimal
treatment method.
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